首頁 > 市場調查報告書 > 製藥

開發平台分析

全球肢端肥大症治療市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

市場調查報告書

商品編碼

1408965

全球肢端肥大症治療市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Acromegaly Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年01月01日 | 出版商:

Value Market Research | 英文 179 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球肢端肥大症治療市場需求預計將從 2023 年的 27.2 億美元增加到 2032 年的近 47.1 億美元，2024-2032 年研究期間CAGR為 6.28%。

肢端肥大症的治療涉及解決生長激素 (GH) 產生過多和組織過度生長的問題，特別是手、腳和臉部的組織，這些組織與肢端肥大症有關。肢端肥大症通常是由腦下垂體良性過度生長引起的，導致 GH 分泌增加。

市場動態

肢端肥大症治療市場是由肢端肥大症的識別、診斷和管理因素所推動的，肢端肥大症是一種罕見的內分泌疾病，其特徵是生長激素分泌過多。在診斷技術進步的幫助下，醫療保健專業人員和公眾的認知不斷提高，可以儘早準確地識別病情。治療方式的進步，包括新的藥物和手術技術，有助於擴大可用的選擇。涉及內分泌科醫生、神經外科醫生和醫療保健專業人員的多學科護理方法增強了患者的整體管理。全球醫療保健支出的增加、患者的倡導努力以及政府支持罕見疾病的舉措進一步推動了市場的發展。研究合作、參與臨床試驗以及全球老年人口的增加等因素促進了肢端肥大症治療格局的持續發展。隨著對肢端肥大症的了解不斷深入，市場有望為診斷出患有這種罕見疾病的個人提供改進和客製化的治療方案。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球肢端肥大症治療市場的各個細分市場進行了包容性評估。肢端肥大症治療產業的成長和趨勢為本研究提供了整體方法。

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲肢端肥大症治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。肢端肥大症治療市場的主要參與者包括諾華公司、易普森製藥公司、太陽製藥工業有限公司、Chiasma Inc.、Peptron Inc.、WOCKHARDT、Dauntless Pharmaceuticals、輝瑞公司、Ionis Pharmaceuticals, Inc.。查看競爭格局，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：肢端肥大症治療公司的競爭格局

肢端肥大症治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
Novartis AG

公司簡介
公司收入
產品
最近的發展

Ipsen Pharma

公司簡介
公司收入
產品
最近的發展

Sun Pharmaceutical Industries LTD.

公司簡介
公司收入
產品
最近的發展

Chiasma Inc.

公司簡介
公司收入
產品
最近的發展

Peptron Inc.

公司簡介
公司收入
產品
最近的發展

WOCKHARDT

公司簡介
公司收入
產品
最近的發展

Dauntless Pharmaceuticals

公司簡介
公司收入
產品
最近的發展

Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

Ionis Pharmaceuticals Inc.

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112113294

The global demand for Acromegaly Treatment Market is presumed to reach the market size of nearly USD 4.71 BN by 2032 from USD 2.72 BN in 2023 with a CAGR of 6.28% under the study period 2024 - 2032.

Acromegaly treatment involves addressing the excessive production of growth hormone (GH) and the overgrowth of tissues, particularly in the hands, feet, and face, associated with the medical condition known as acromegaly. Acromegaly is typically caused by the benign overgrowth of the pituitary gland, leading to increased GH secretion.

MARKET DYNAMICS

The Acromegaly treatment market is driven by factors contributing to the recognition, diagnosis, and management of acromegaly, a rare endocrine disorder characterized by excessive growth hormone production. Increasing awareness among healthcare professionals and the general public, aided by advancements in diagnostic technologies, leads to early and accurate identification of the condition. Advances in treatment modalities, including novel medications and surgical techniques, contribute to the expansion of available options. The multidisciplinary care approach involving endocrinologists, neurosurgeons, and healthcare professionals enhances overall patient management. Rising healthcare expenditure globally, patient advocacy efforts, and government initiatives supporting rare diseases further drive the market. Collaboration in research, participation in clinical trials, and a global rise in the geriatric population, among other factors, contribute to the evolving landscape of Acromegaly treatment. As understanding of acromegaly progresses, the market is poised to offer improved and tailored treatment options for individuals diagnosed with this uncommon disorder.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of acromegaly treatment. The growth and trends of acromegaly treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the acromegaly treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

Somatostatin Analogs
GHRA
Others

By End-Use

Hospitals & Clinics
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Acromegaly Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Acromegaly Treatment market include Novartis AG, Ipsen Pharma, Sun Pharmaceutical Industries LTD., Chiasma Inc., Peptron Inc., WOCKHARDT, Dauntless Pharmaceuticals, Pfizer Inc., Ionis Pharmaceuticals, Inc.. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ACROMEGALY TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Type
- 3.7.2 Market Attractiveness Analysis By End-use
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ACROMEGALY TREATMENT MARKET ANALYSIS BY DRUG TYPE

5.1 Overview by Drug Type
5.2 Historical and Forecast Data
5.3 Analysis by Drug Type
5.4 Somatostatin analogs Historic and Forecast Sales by Regions
5.5 GHRA Historic and Forecast Sales by Regions
5.6 Others Historic and Forecast Sales by Regions

6 . GLOBAL ACROMEGALY TREATMENT MARKET ANALYSIS BY END-USE

6.1 Overview by End-use
6.2 Historical and Forecast Data
6.3 Analysis by End-use
6.4 Hospitals & Clinics Historic and Forecast Sales by Regions
6.5 Others Historic and Forecast Sales by Regions

7 . GLOBAL ACROMEGALY TREATMENT MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE ACROMEGALY TREATMENT COMPANIES

8.1. Acromegaly Treatment Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF ACROMEGALY TREATMENT INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Novartis AG
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Ipsen Pharma
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. Sun Pharmaceutical Industries LTD.
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. Chiasma Inc.
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Peptron Inc.
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. WOCKHARDT
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Dauntless Pharmaceuticals
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. Pfizer Inc.
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Ionis Pharmaceuticals Inc.
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments